Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Pollack CV Jr, et al. Among authors: van ryn j. N Engl J Med. 2017 Aug 3;377(5):431-441. doi: 10.1056/NEJMoa1707278. Epub 2017 Jul 11. N Engl J Med. 2017. PMID: 28693366 Free article. Clinical Trial.
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J. Glund S, et al. Among authors: van ryn j. Lancet. 2015 Aug 15;386(9994):680-90. doi: 10.1016/S0140-6736(15)60732-2. Epub 2015 Jun 15. Lancet. 2015. PMID: 26088268 Clinical Trial.
Idarucizumab: The Antidote for Reversal of Dabigatran.
Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Eikelboom JW, et al. Among authors: van ryn j. Circulation. 2015 Dec 22;132(25):2412-22. doi: 10.1161/CIRCULATIONAHA.115.019628. Circulation. 2015. PMID: 26700008 Review. No abstract available.
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
Glund S, Stangier J, van Ryn J, Schmohl M, Moschetti V, Haazen W, De Smet M, Gansser D, Norris S, Lang B, Reilly P, Kreuzer J. Glund S, et al. Among authors: van ryn j. Clin Pharmacokinet. 2017 Jan;56(1):41-54. doi: 10.1007/s40262-016-0417-0. Clin Pharmacokinet. 2017. PMID: 27317414 Free PMC article. Clinical Trial.
Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
Glund S, Reilly P, van Ryn J, Stangier J. Glund S, et al. Among authors: van ryn j. Clin Pharmacokinet. 2017 Feb;56(2):209-210. doi: 10.1007/s40262-016-0493-1. Clin Pharmacokinet. 2017. PMID: 28028767 Free PMC article. No abstract available.
80 results